Patient and disease characteristics
| Characteristic . | Number of patients . | Percent . |
|---|---|---|
| No. of patients | 21 | 100 |
| Sex | ||
| Male | 13 | 62 |
| Female | 8 | 38 |
| Age, y | ||
| Median (range) | 66 | |
| Range | 22-77 | |
| ECOG performance status | ||
| 0-1 | 13 | 62 |
| >1 | 8 | 38 |
| Ann Arbor stage | ||
| III-IV | 19 | 90 |
| LDH | ||
| Normal | 11 | 52 |
| Elevated | 10 | 48 |
| Bone marrow involvement | ||
| Yes | 7 | 33 |
| No | 13 | 62 |
| Unknown | 1 | 5 |
| PTCL subtypes | ||
| PTCL-TFH | 17 | 81 |
| PTCL-NOS | 3 | 14 |
| ATLL | 1 | 5 |
| IPI risk category | ||
| 0-1 | 5 | 24 |
| 2 | 7 | 33 |
| 3 | 3 | 14 |
| 4-5 | 6 | 29 |
| CD30 expression | ||
| Positive (≥10%) | 4 | 19 |
| Negative (<10%) | 17 | 81 |
| Characteristic . | Number of patients . | Percent . |
|---|---|---|
| No. of patients | 21 | 100 |
| Sex | ||
| Male | 13 | 62 |
| Female | 8 | 38 |
| Age, y | ||
| Median (range) | 66 | |
| Range | 22-77 | |
| ECOG performance status | ||
| 0-1 | 13 | 62 |
| >1 | 8 | 38 |
| Ann Arbor stage | ||
| III-IV | 19 | 90 |
| LDH | ||
| Normal | 11 | 52 |
| Elevated | 10 | 48 |
| Bone marrow involvement | ||
| Yes | 7 | 33 |
| No | 13 | 62 |
| Unknown | 1 | 5 |
| PTCL subtypes | ||
| PTCL-TFH | 17 | 81 |
| PTCL-NOS | 3 | 14 |
| ATLL | 1 | 5 |
| IPI risk category | ||
| 0-1 | 5 | 24 |
| 2 | 7 | 33 |
| 3 | 3 | 14 |
| 4-5 | 6 | 29 |
| CD30 expression | ||
| Positive (≥10%) | 4 | 19 |
| Negative (<10%) | 17 | 81 |
ECOG, Eastern Clinical Oncology Group; LDH, lactate dehydrogenase; IPI, international prognostic index.